Conduit Change In Cash from 2010 to 2025

CDTTW Stock   0.01  0.0001  0.89%   
Conduit Pharmaceuticals Change In Cash yearly trend continues to be fairly stable with very little volatility. Change In Cash is likely to outpace its year average in 2025. During the period from 2010 to 2025, Conduit Pharmaceuticals Change In Cash regression line of quarterly data had mean square error of 4156.3 T and geometric mean of  603,372. View All Fundamentals
 
Change In Cash  
First Reported
2010-12-31
Previous Quarter
-226.7 M
Current Value
-215.4 M
Quarterly Volatility
75.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Conduit Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Conduit Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 143.6 K, Selling General Administrative of 4.1 M or Total Revenue of 2.6 B, as well as many indicators such as Price To Sales Ratio of 0.088, Dividend Yield of 0.0235 or PTB Ratio of 0.23. Conduit financial statements analysis is a perfect complement when working with Conduit Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Conduit Pharmaceuticals Correlation against competitors.
For more information on how to buy Conduit Stock please use our How to Invest in Conduit Pharmaceuticals guide.

Latest Conduit Pharmaceuticals' Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Conduit Pharmaceuticals over the last few years. It is Conduit Pharmaceuticals' Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Conduit Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Slightly volatile
   Change In Cash   
100%
       Timeline  

Conduit Change In Cash Regression Statistics

Arithmetic Mean(27,503,939)
Geometric Mean603,372
Coefficient Of Variation(274.86)
Mean Deviation48,392,378
Median(203,445)
Standard Deviation75,598,148
Sample Variance5715.1T
Range231M
R-Value(0.57)
Mean Square Error4156.3T
R-Squared0.32
Significance0.02
Slope(8,999,663)
Total Sum of Squares85726.2T

Conduit Change In Cash History

2025-215.4 M
2024-226.7 M
20234.2 M
2022297.2 K

About Conduit Pharmaceuticals Financial Statements

Conduit Pharmaceuticals investors use historical fundamental indicators, such as Conduit Pharmaceuticals' Change In Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Conduit Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Cash-226.7 M-215.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Conduit Stock Analysis

When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…